Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells

Immunobiology

Volumn 207, Issue 2, 2003, Pages 85-93

  Clausen, Johannes ^a   Vergeiner, Birgit ^a   Enk, Martina ^a   Petzer, Andreas L ^a   Gastl, Günther ^a   Gunsilius, Eberhard ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CD16 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; INTERLEUKIN 2 RECEPTOR; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; THYMIDINE;

ADULT; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; BLOOD CULTURE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL ASSAY; CELL COUNT; CELL FRACTIONATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DATA ANALYSIS; DNA SYNTHESIS; EFFECTOR CELL; EXPERIMENTATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE CULTURE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; NATURAL KILLER CELL; PREDICTION; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; T LYMPHOCYTE;

EID: 0037240579     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1078/0171-2985-00219     Document Type: Review

References (29)

1. Anegon I, Cuturi MC, Trinchieri G and Perussia B. 1988. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J. Exp. Med. 167: 452-472.
2. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE et al. 1992. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J. Clin. Oncol. 10: 102-110.
3. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K and Goldfarb RH. 1991. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J. Exp. Med. 174: 479-488.
4. Beitsch P, Lotzova E, Hortobagyi G and Pollock R. 1994. Natural immunity in breast cancer patients during neoadjuvant chemotherapy and after surgery. Surg. Oncol. 3: 211-219.
5. Bix M and Locksley RM. 1995. Natural T-cells: cells that co-express NKRP-1 and TCR. J. Immunol. 155: 1020-1022.
6. Borrego F, Robertson M, Ritz J, Pena J and Solana R. 1999. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology. 97: 159-165.
7. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA and Ritz J. 1990. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J. Exp. Med. 171: 1509-1526.
8. + lymphocytes from patients undergoing autologous peripheral blood stem cell transplantation. J. Hematother. Stem Cell Res. 10: 513-521.
9. Craston R, Koh M, McDermott A, Ray N, Prentice HG and Lowdell MW. 1997. Temporal dynamics of CD69 expression on lymphoid cells. J. Immunol. Methods. 209: 37-45.
10. - T-cells. J. Exp. Med. 186: 109-120.
11. Hatam L, Schuval S and Bonagura VR. 1994. Flow cytometric analysis of natural killer cell function as a clinical assay. Cytometry. 16: 59-68.
12. Hoshino S, Oshimi K, Teramura M and Mizoguchi H. 1991. Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders. Blood. 78: 3232-3240.
13. Jewett A and Bonavida B. 1995. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J. Clin. Immunol. 15: 35-44.
14. Lanier LL, Buck DW, Rhodes L, Ding A, Evans E, Barney C and Phillips JH. 1988. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen. J. Exp. Med. 167: 1572-1585.
15. Lauzurica P, Sancho D, Torres M, Albella B, Marazuela M, Merino T, Bueren JA, Martinez A and Sanchez-Madrid F. 2000. Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice. Blood. 95: 2312-2320.
16. Lebow LT, Jewett A and Bonavida B. 1993. Killer cell recruitment and renewal capacity of purified cytolytic and noncytolytic human peripheral blood natural killer cell subsets. J. Immunol. 150: 320-329.
17. + cells derived from T-cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153: 1687-1696.
18. McCulloch PG and MacIntyre A. 1993. Effects of surgery on the generation of lymphokine-activated killer cells in patients with breast cancer. Br. J. Surg. 80: 1005-1007.
19. Miller JS, Prosper F and McCullar V. 1997. Natural killer (NK) cells are functionally abnormal and NK-cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. Blood. 90: 3098-3105.
20. Moretta A, Poggi A, Pende D, Tripodi G, Orengo AM, Pella N, Augugliaro R, Bottino C, Ciccone E and Moretta L. 1991. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T-cell receptor alpha/beta. J. Exp. Med. 174: 1393-1398.
21. Nagler A, Lanier LL and Phillips JH. 1990. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J. Exp. Med. 171: 1527-1533.
22. Rondelli D, Raspadori D, Anasetti C, Bandini G, Re F, Arpinati M, Stanzani M, Morelli A, Baccini C, Zaccaria A, Lemoli RM and Tura S. 1998. Alloantigen presenting capacity, T-cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplant. 22: 631-937.
23. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, E. Shiloni E, Vetto JT et al. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313: 1485-1492.
24. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA et al. 1993. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85: 622-632.
25. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL and Negrin RS. 1993. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp. Hematol. 21: 1673-1679.
26. Sewell HF, Halbert CF, Robins RA, Galvin A, Chan S and Blamey RW. 1993. Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer. Int. J. Cancer. 55: 735-738.
27. Siegel JP, Sharon M, Smith PL and Leonard WJ. 1987. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science. 238: 75-78.
28. Trinchieri G. 1989. Biology of natural killer cells. Adv. Immunol. 47: 187-376.
29. Vujanovic NL, Rabinowich H, Lee YJ, Jost L, Herberman RB, and Whiteside TL. 1993. Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic. Cell. Immunol. 151: 133-157.